Question-and-Answer Session
Operator
Certainly. (Operator instructions). And we will take our first question Joel Sendek with Lazard.
Joel Sendek
Thanks two questions on the new study, the new 015 study did you disclose what the doses that you will be using?
Dr. Dan Burge
We have not disclosed the dose in that study.
Joel Sendek
Okay. Can you tell me whether there was one of the doses from the Phase 2b?
Dr. Dan Burge
Yes, it is.
Joel Sendek
It is, okay. And next why did you choose ACR50 as a primary?
Dr. Dan Burge
ACR50 is one of the accepted end points have fused in clinical studies, it’s been imprecated with other clinical products, so that was a preference of our partners.
Joel Sendek
Okay. And then second question on 087, can you talk about the IP status of that and whether it is separate, do you have a separate IP as it might be stronger than 015?
Dr. Peter Thompson
Hi Joel, this is Peter.
Joel Sendek
Hi, Peter.
Dr. Peter Thompson
The SBI-087 is a different molecule than TRU-015 and so it may enjoy somewhat different patent protection whether that ultimately proves to be stronger than the pattern protection for TRU-015, which we believe to be strong, remains to be seen as things move forward both in the patent office and elsewhere.
Joel Sendek
And could it potentially infringe in the Genentech IP, the same way 015 dose or what the upside of that?
Dr. Peter Thompson
It is a CD20 directed therapy as TRU-015 is and to the extent that you are referencing the matter that we are opposing in Europe that is directed to CD20 directive therapies.
Joel Sendek
Okay, great. Thanks a lot.
Operator
(Operator instructions). And it appears we have no further questions. Dr. Thompson I will hand the conference back to you for any closing comments.
Dr. Peter Thompson
Well, I would like to thank everyone again for their continued interest and support of Trubion and we look forward to speaking with you again soon.
Operator
And that will conclude our conference. Again thank you all for your participation. Please enjoy the rest of your day.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
- To read the full transcript on Seeking Alpha, click here »
